Annals of surgery · 2024
Unraveling the Long-term Natural History of Branch Duct Intraductal Papillary Mucinous Neoplasm: Beyond 10 years.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Assawasirisin Charnwit, Fagenholz Peter, Qadan Motaz, Hernandez-Barco Yasmin, Aimprasittichai Satita, Kambadakone Avinash, Mino-Kenudson Mari, Ike Amarachi, Chen Sheng-Yin, Sheng Chen, Brugge William, Warshaw Andrew L, Lillemoe Keith D, Fernández-Del Castillo Carlos
Аннотация
OBJECTIVE: To describe the long-term natural history of branch duct intraductal papillary mucinous neoplasm (BD-IPMN).
BACKGROUND: The BD-IPMN is a known precursor of pancreatic cancer, yet its long-term natural history is largely unknown.
METHODS: We retrospectively reviewed patients with BD-IPMN who were followed at the Massachusetts General Hospital for at least 10 years without surgical intervention. Patient and cyst characteristics, development of worrisome features (WF), need for surgery, and malignancy were recorded. The risk of pancreatic cancer in this cohort was compared with the general population by determining the standardized incidence ratio.
RESULTS: Three hundred sixteen patients with BD-IPMN who were followed for at least 10 years without intervention were identified. The median age was 63 years, and the median follow-up was 13.5 years (range: 10-28.8 years). Median cyst size at diagnosis was 1.2 cm (IQR: 0.8-1.7), was 1.8 cm (IQR: 1.2-2.6) at 10 years, and increased to 2.0 cm (IQR: 1.3-3.0) by the end of surveillance. At the 10-year mark, 24% of patients had WF, and by the end of surveillance, an additional 20% had developed WF or high-risk stigmata. 8.2% of patients developed pancreatic malignancy (high-grade dysplasia or invasive cancer). The standardized incidence ratio for pancreatic cancer was 9.28 (95% CI: 5.82-14.06), with almost two-thirds of invasive cancers occurring within the pancreatic cyst.
CONCLUSIONS: After 10 years of surveillance for BD-IPMN without intervention, the disease continues to progress, and 1 of every 12 patients will develop malignancy. The risk of pancreatic cancer appears to be 9 times higher than in the comparable age-matched population.
BACKGROUND: The BD-IPMN is a known precursor of pancreatic cancer, yet its long-term natural history is largely unknown.
METHODS: We retrospectively reviewed patients with BD-IPMN who were followed at the Massachusetts General Hospital for at least 10 years without surgical intervention. Patient and cyst characteristics, development of worrisome features (WF), need for surgery, and malignancy were recorded. The risk of pancreatic cancer in this cohort was compared with the general population by determining the standardized incidence ratio.
RESULTS: Three hundred sixteen patients with BD-IPMN who were followed for at least 10 years without intervention were identified. The median age was 63 years, and the median follow-up was 13.5 years (range: 10-28.8 years). Median cyst size at diagnosis was 1.2 cm (IQR: 0.8-1.7), was 1.8 cm (IQR: 1.2-2.6) at 10 years, and increased to 2.0 cm (IQR: 1.3-3.0) by the end of surveillance. At the 10-year mark, 24% of patients had WF, and by the end of surveillance, an additional 20% had developed WF or high-risk stigmata. 8.2% of patients developed pancreatic malignancy (high-grade dysplasia or invasive cancer). The standardized incidence ratio for pancreatic cancer was 9.28 (95% CI: 5.82-14.06), with almost two-thirds of invasive cancers occurring within the pancreatic cyst.
CONCLUSIONS: After 10 years of surveillance for BD-IPMN without intervention, the disease continues to progress, and 1 of every 12 patients will develop malignancy. The risk of pancreatic cancer appears to be 9 times higher than in the comparable age-matched population.